Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. Natera, Inc. has collaboration partnership with Fox Chase Cancer Center to assess customized circulating tumor DNA assay for recurrence monitoring of kidney cancer. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090
Debt
Debt-to-Equity Ratio-3.32
Current Ratio1.69
Quick Ratio1.56
Price-To-Earnings
Trailing P/E Ratio-10.50
Forward P/E Ratio-12.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$210.94 million
Price / Sales7.28
Cash FlowN/A
Price / CashN/A
Book Value($0.19) per share
Price / Book-132.63
Profitability
EPS (Most Recent Fiscal Year)($2.40)
Net Income$-136,310,000.00
Net Margins-59.07%
Return on Equity-752.93%
Return on Assets-64.29%
Miscellaneous
Employees893
Outstanding Shares60,940,000
Market Cap$1.47 billion
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) announced its quarterly earnings data on Wednesday, August, 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.55). The medical research company earned $63.07 million during the quarter, compared to the consensus estimate of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The business's revenue for the quarter was up 20.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.55) EPS. View Natera's Earnings History.
When is Natera's next earnings date?
What price target have analysts set for NTRA?
6 brokers have issued twelve-month price targets for Natera's shares. Their forecasts range from $12.00 to $30.00. On average, they expect Natera's share price to reach $23.00 in the next year. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for Natera.
What is the consensus analysts' recommendation for Natera?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.
Are investors shorting Natera?
Natera saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 1,074,198 shares, a decline of 28.8% from the July 31st total of 1,509,612 shares. Based on an average daily volume of 597,830 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.8% of the shares of the stock are short sold. View Natera's Current Options Chain.
Who are some of Natera's key competitors?
Some companies that are related to Natera include ELEKTA AB/ADR (EKTAY), Foundation Medicine (FMI), Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS) and Cancer Genetics (CGIX).
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz, Co-Founder, CEO, Pres & Chairman (Age 45)
- Mr. Michael Brophy, Chief Financial Officer (Age 38)
- Mr. Steve Chapman, Chief Operating Officer (Age 39)
- Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 45)
- Mr. Daniel Rabinowitz L.L.M., LL.M., Sec. & Gen. Counsel
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Who are Natera's major shareholders?
Natera's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (4.80%), BlackRock Inc. (3.83%), Fred Alger Management Inc. (3.24%), Macquarie Group Ltd. (2.81%), Orbimed Advisors LLC (1.61%) and Renaissance Technologies LLC (1.45%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.
Which major investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Asymmetry Capital Management L.P., Broadview Advisors LLC, Kornitzer Capital Management Inc. KS, Contrarius Investment Management Ltd, Spark Investment Management LLC, Strs Ohio and Capital Impact Advisors LLC. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.
Which major investors are buying Natera stock?
NTRA stock was bought by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Millennium Management LLC, BlackRock Inc., Renaissance Technologies LLC, EAM Investors LLC, Essex Investment Management Co. LLC, Macquarie Group Ltd. and Tygh Capital Management Inc.. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $25.20.
How big of a company is Natera?
Natera has a market capitalization of $1.47 billion and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.
What is Natera's official website?
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.
MarketBeat Community Rating for Natera (NASDAQ NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
